Search global stocks & ETFs...Ctrl K
Learn Mode
INCY
Stock Profile
07-27
Recommended Metric
Score Card
Explore Scores Tab
3.96
Good
Valuation Score
Key Score
4.00
Good
Management
5.00
Very Good
Growth
5.00
Very Good
Profitability
3.00
Average
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$116.86
Baseline
High
$141.75
▲
21.30%
Avg
$110.72
▼
-5.25%
Low
$72.83
▼
-37.68%
Analyst Ratings based on 35 Analysts
Strong Buy
823%
Buy
823%
Hold
1851%
Sell
103%
Strong Sell
000%
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.Read More